16 results on '"Walter M. Gregory"'
Search Results
2. Extended follow‐up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat ( <scp>MUK</scp> six open label, multi‐centre phase I/ <scp>II</scp> Clinical Trial)
- Author
-
Rakesh Popat, Kwee Yong, Jamie Cavenagh, Andrew J. Hall, Sarah Brown, Heather Oakervee, Bhuvan Kishore, Walter M Gregory, Matthew Streetly, Louise Flanagan, Eric Low, and Gordon Cook
- Subjects
Oncology ,Bortezomib/thalidomide ,medicine.medical_specialty ,business.industry ,Hematology ,medicine.disease ,Clinical trial ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,chemistry ,030220 oncology & carcinogenesis ,Internal medicine ,Panobinostat ,medicine ,Multi centre ,Open label ,business ,Survival rate ,Multiple myeloma ,Dexamethasone ,030215 immunology ,medicine.drug - Published
- 2018
3. Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma IX randomised study
- Author
-
Graham Jackson, Graham P. Cook, J. A. Child, Gareth J. Morgan, Roger G. Owen, Mark T. Drayson, Walter M Gregory, Faith E. Davies, Sue E. Bell, David A Cairns, and Kara-Louise Royle
- Subjects
Male ,Melphalan ,Oncology ,Zoledronic Acid ,0302 clinical medicine ,Quality of life ,Surveys and Questionnaires ,Antineoplastic Combined Chemotherapy Protocols ,Longitudinal Studies ,Multiple myeloma ,Haematological Malignancy ,Remission Induction ,Hematopoietic Stem Cell Transplantation ,EORTC QLQ‐C30 ,Hematology ,Middle Aged ,humanities ,Thalidomide ,3. Good health ,multiple myeloma ,030220 oncology & carcinogenesis ,Prednisolone ,EORTC MY‐24 ,Female ,Research Paper ,medicine.drug ,Adult ,medicine.medical_specialty ,Adolescent ,Cyclophosphamide ,Transplantation, Autologous ,Maintenance Chemotherapy ,Young Adult ,03 medical and health sciences ,immunomodulatory agent ,Internal medicine ,medicine ,Humans ,Dexamethasone ,Aged ,business.industry ,medicine.disease ,Consolidation Chemotherapy ,Zoledronic acid ,quality of life ,Self Report ,Clodronic Acid ,business ,030215 immunology - Abstract
Summary In the Medical Research Council (MRC) Myeloma IX trial (ISRCTN684564111) patients were randomised to sodium clodronate or zoledronic acid and induction treatment: cyclophosphamide, vincristine, doxorubicin and dexamethasone (CVAD) or cyclophosphamide, thalidomide and dexamethasone (CTD) followed by autologous stem cell transplant (ASCT) in the intensive pathway; attenuated CTD or melphalan and prednisolone (MP) in the non‐intensive pathway. Subsequent randomisation allocated patients to either thalidomide or observation. The European Organisation for Research and Treatment of Cancer (EORTC) quality of life (QoL) questionnaires, QLQ‐C30 and QLQ‐MY24, were administered at baseline, 3, 6 and 12 months and annually thereafter, enabling the effect of sequential treatment on patient‐reported health‐related QoL (HR‐QoL) to be investigated. The protocol specified four subscales of interest: Pain, Fatigue, Global Health Status/Quality of Life and Physical Functioning at 3, 6 and 12 months that were compared using linear models. The intensive pathway showed significant differences in favour of CTD for Fatigue at 3 months and Physical Functioning at 12 months. The non‐intensive pathway and maintenance phase reported significant differences at 3 months; Pain (improved with attenuated CTD) and Global Health status/Quality of Life (improved with observation). The improved outcomes in MRC Myeloma IX were accompanied by some beneficial and few detrimental effects on HR‐QoL.
- Published
- 2018
4. Diagnosis and monitoring for light chain only and oligosecretory myeloma using serum free light chain tests
- Author
-
J. Anthony Child, Jennifer L J Heaney, Mark T. Drayson, Meena Shemar, Gareth J. Morgan, Anne E Griffin, Graham Jackson, Walter M Gregory, Jane Birtwistle, David A Cairns, and John Campbell
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Response to therapy ,Point-of-Care Systems ,Concordance ,Aftercare ,Immunoglobulins ,Urine ,Immunoglobulin light chain ,Sensitivity and Specificity ,Gastroenterology ,Disease-Free Survival ,03 medical and health sciences ,0302 clinical medicine ,Serum free ,Internal medicine ,Journal Article ,medicine ,Humans ,Multiple myeloma ,Retrospective Studies ,Immunoassay ,Very Good Partial Response ,medicine.diagnostic_test ,business.industry ,Hematology ,medicine.disease ,030104 developmental biology ,030220 oncology & carcinogenesis ,Immunology ,Immunoglobulin Light Chains ,Neoplasm Recurrence, Local ,Multiple Myeloma ,business - Abstract
This study aims to guide the integration of serum free light chain (sFLC) tests into clinical practice, including a new rapid test (Seralite(®) ). Blood and urine analysis from 5573 newly diagnosed myeloma patients identified 576 light chain only (LCO) and 60 non-secretory (NS) cases. Serum was tested by Freelite(®) and Seralite(®) at diagnosis, maximum response and relapse. 20% of LCO patients had urine FLC levels below that recommended for measuring response but >97% of these had adequate sFLC levels (oligosecretory). The recommended Freelite(®) sFLC ≥100 mg/l for measuring response was confirmed and the equivalent Seralite(®) FLC difference (dFLC) >20 mg/l identified. By both methods, ≥38% of NS patients had measurable disease (oligosecretory). Higher sFLC levels were observed on Freelite(®) at all time points. However, good clinical concordance was observed at diagnosis and in response to therapy. Achieving at least a very good partial response according to either sFLC method was associated with better patient survival. Relapse was identified using a Freelite(®) sFLC increase >200 mg/l and found 100% concordance with a corresponding Seralite(®) dFLC increase >30 mg/l. Both Freelite(®) and Seralite(®) sensitively diagnose and monitor LCO/oligosecretory myeloma. Rapid testing by Seralite(®) could fast-track FLC screening and monitoring. Response by sFLC assessment was prognostic for survival and demonstrates the clinical value of routine sFLC testing.
- Published
- 2017
5. Abstracts
- Author
-
Charlotte Pawlyn, Alina Striha, Mark T. Drayson, de, Tute, Rm, John R Jones, Walter M Gregory, David A Cairns, Andy C. Rawstron, Martin Kaiser, Graham Jackson, G. J. Morgan, Faith E. Davies, Anna Chalmers, Graham P. Cook, Roger G. Owen, Corinne Collett, and Nigel H. Russell
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,Internal medicine ,Medicine ,Hematology ,business ,Transplant ineligible ,Outcome (game theory) ,Minimal residual disease - Published
- 2016
6. Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKonerandomized dose selection trial
- Author
-
Walter M Gregory, Guillermo Orti, Avie-Lee Tillotson, Faith E. Davies, Cathy Williams, Kwee Yong, Mark Cook, James Cavet, Gordon Cook, Curly Morris, Sarah Brown, Louise Flanagan, Steve Schey, Gareth J. Morgan, Debbie Sherratt, and Jamie Cavenagh
- Subjects
Adult ,Male ,Bendamustine ,Melphalan ,Oncology ,medicine.medical_specialty ,Population ,Dexamethasone ,Disease-Free Survival ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Bendamustine Hydrochloride ,Humans ,education ,Multiple myeloma ,Aged ,Lenalidomide ,Aged, 80 and over ,education.field_of_study ,Bortezomib ,business.industry ,Hematology ,Middle Aged ,medicine.disease ,Thalidomide ,Surgery ,Survival Rate ,Nitrogen Mustard Compounds ,Female ,Multiple Myeloma ,business ,medicine.drug - Abstract
There is a significant unmet need in effective therapy for relapsed myeloma patients once they become refractory to bortezomib and lenalidomide. While data from the front line setting suggest bendamustine is superior to melphalan, there is no information defining optimal bendamustine dose in multiply-treated patients. We report a multi-centre randomized two-stage phase 2 trial simultaneously assessing deliverability and activity of two doses of bendamustine (60 mg/m2 vs. 100 mg/m2) days 1 and 8, thalidomide (100 mg) days 1-21 and low dose dexamethasone (20 mg) days 1, 8, 15 and 22 of a 28-d cycle. Ninety-four relapsing patients were treated on trial, with a median three prior treatment lines. A pre-planned interim deliverability and activity assessment led to closure of the 100 mg/m2 arm due to excess cytopenias, and led to amendment of entry criteria for cytopenias. Non-haematological toxicities including thromboembolism and neurotoxicity were infrequent. In the 60 mg/m2 arm, treatment was deliverable in 61.1% subjects and the partial response rate was 46.3% in the study eligible population, with 7.5 months progression-free survival. This study demonstrates bendamustine at 60 mg/m2 twice per month with thalidomide and dexamethasone is deliverable for repeated cycles in heavily pre-treated myeloma patients and has substantial clinical activity.
- Published
- 2015
7. Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results
- Author
-
Sue E. Bell, AJ Szubert, Kevin Boyd, Walter M Gregory, Sylvia Feyler, Claudius Rudin, Gareth J. Morgan, Roger G. Owen, Nuria Navarro Coy, Mark T. Drayson, Graham Jackson, Jennifer Byrne, A J Ashcroft, Faith E. Davies, Huw Roddie, J. Anthony Child, Gordon Cook, Fiona M. Ross, Wendy Osborne, and Ping Wu
- Subjects
Adult ,Male ,medicine.medical_specialty ,medicine.medical_treatment ,Osteolysis ,Zoledronic Acid ,Gastroenterology ,Drug Administration Schedule ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Adverse effect ,Multiple myeloma ,Aged ,Aged, 80 and over ,Chemotherapy ,Bisphosphonate-associated osteonecrosis of the jaw ,Bone Density Conservation Agents ,Diphosphonates ,business.industry ,Incidence ,Incidence (epidemiology) ,Imidazoles ,Hematology ,Acute Kidney Injury ,Middle Aged ,medicine.disease ,Surgery ,Zoledronic acid ,England ,Clodronic acid ,Bisphosphonate-Associated Osteonecrosis of the Jaw ,Female ,Clodronic Acid ,Multiple Myeloma ,Osteonecrosis of the jaw ,business ,Follow-Up Studies ,medicine.drug - Abstract
Bisphosphonates are recommended in patients with osteolytic lesions secondary to multiple myeloma. We report on the safety of bisphosphonate therapy with long-term follow-up in the Medical Research Council Myeloma IX study. Patients with newly diagnosed multiple myeloma were randomised to zoledronic acid (ZOL; 4 mg intravenously every 21-28 d) or clodronate (CLO; 1600 mg/d orally) plus chemotherapy. Among 1960 patients (5.9-year median follow-up), both bisphosphonates were well tolerated. Acute renal failure events were similar between groups (ZOL 5.2% vs. CLO 5.8% at 2 years; incidence plateaued thereafter). The overall incidence of confirmed osteonecrosis of the jaw (ONJ) was low, but higher with ZOL (ZOL 3.7% vs. CLO 0.5%; P < 0.0001). ONJ events were generally low grade and most occurred between 8 and 30 months (median time to ONJ, 23.7 months). Among 10 patients with ONJ recovery data, four patients in the ZOL group completely recovered, two patients improved, and three patients experienced no improvement; one CLO patient experienced no improvement. Dental surgery or trauma preceded ONJ in six ZOL patients. The incidence of renal adverse events was similar for ZOL and CLO. ONJ incidence remained low and was lower with CLO compared to ZOL. We have seen no further ONJ cases to date.
- Published
- 2014
8. Radiofrequency ablation (RFA) of renal cell carcinoma (RCC): experience in 200 tumours
- Author
-
Tze Min Wah, Walter M Gregory, H. C. Irving, Jon Cartledge, Peter Selby, and Adrian D. Joyce
- Subjects
medicine.medical_specialty ,Percutaneous ,medicine.diagnostic_test ,Radiofrequency ablation ,business.industry ,Urology ,Renal function ,Magnetic resonance imaging ,medicine.disease ,law.invention ,Dissection ,law ,Renal cell carcinoma ,medicine ,Radiology ,Complication ,business ,Acute tubular necrosis - Abstract
Objectives To evaluate our clinical experience with percutaneous image-guided radiofrequency ablation (RFA) of 200 renal tumours in a large tertiary referral university institution. Patients and Methods Image-guided RFA (ultrasonography or computed tomography [CT]) of 200 renal tumours in 165 patients from June 2004 to 2012 was prospectively evaluated. Institutional Review Board approval was granted. The treatment response and technical success were defined by absence of contrast enhancement within the tumour on contrast enhanced CT or magnetic resonance imaging. Both major and minor complications, glomerular filtration rate (GFR) before and after RFA, the management and outcomes of the complications, as well as oncological outcome were prospectively documented. Multivariate analysis was used to determine variables associated with major complications and also the percentage GFR change after RFA. The overall (OS), 5-year cancer-specific (CSS), local recurrence-free (LRFS) and metastasis-free survival (MFS) rates are presented using the Kaplan–Meier curves. Results In all, 200 tumours were RF ablated with a mean (range) tumour size of 2.9 (1–5.6) cm and the mean (range) patient age was 67.7 (21–88.6) years with a mean follow-up period of 46.1 months. The primary technical and overall technical success rate was 95.5% and 98.5%, respectively. Two independent predictors of successful RFA in a single sitting were tumour size (25% decreased in GFR. In all, 161 (98%) patients of the 165 patients have preservation of renal function. Any change in renal function after RFA was not influenced by tumour factors or solitary kidney status. In our clinical series, this yielded a 5-year OS, CSS, LRFS and MFS rates of 75.8%, 97.9%, 93.5% and 87.7% respectively. Conclusions Image-guided RFA is a safe, nephron sparing and effective treatment for small renal cell carcinoma (RCC) tumours with a low rate of recurrence and has good 5-year CSS and MFS rates.
- Published
- 2013
9. Improved risk stratification in myeloma using a microRNA-based classifier
- Author
-
Christopher P. Wardell, David W. Johnson, Antonino Neri, Luca Agnelli, Gareth J. Morgan, Martin Kaiser, Ping Wu, Marta Lionetti, Brian A Walker, Katia Todoerti, Faith E. Davies, Daniel Brewer, Walter M Gregory, and Fabio Mirabella
- Subjects
Kaplan-Meier Estimate ,Disease ,Computational biology ,Biology ,Bioinformatics ,Risk Assessment ,microRNA ,Gene expression ,Biomarkers, Tumor ,medicine ,Humans ,RNA, Neoplasm ,Gene ,In Situ Hybridization, Fluorescence ,Multiple myeloma ,Aged ,Chromosome Aberrations ,Regulation of gene expression ,Gene Expression Profiling ,Hematology ,Middle Aged ,Prognosis ,medicine.disease ,Gene Expression Regulation, Neoplastic ,Gene expression profiling ,MicroRNAs ,Multiple Myeloma ,Classifier (UML) - Abstract
Multiple myeloma (MM) is a heterogeneous disease. International Staging System/fluorescence hybridization (ISS/FISH)-based model and gene expression profiles (GEP) are effective approaches to define clinical outcome, although yet to be improved. The discovery of a class of small non-coding RNAs (micro RNAs, miRNAs) has revealed a new level of biological complexity underlying the regulation of gene expression. In this work, 163 presenting samples from MM patients were analysed by global miRNA profiling, and distinct miRNA expression characteristics in molecular subgroups with prognostic relevance (4p16, MAF and 11q13 translocations) were identified. Furthermore we developed an "outcome classifier", based on the expression of two miRNAs (MIR17 and MIR886-5p), which is able to stratify patients into three risk groups (median OS 19.4, 40.6 and 65.3 months, P = 0.001). The miRNA-based classifier significantly improved the predictive power of the ISS/FISH approach (P = 0.0004), and was independent of GEP-derived prognostic signatures (P < 0.002). Through integrative genomics analysis, we outlined the potential biological relevance of the miRNAs included in the classifier and their putative roles in regulating a large number of genes involved in MM biology. This is the first report showing that miRNAs can be built into molecular diagnostic strategies for risk stratification in MM.
- Published
- 2013
10. Cyclin D1 and prognosis in human breast cancer
- Author
-
Diana M. Barnes, Michael Richards, Walter M Gregory, Gordon Peters, Cheryl Gillett, Rosemary R. Millis, and P. Smith
- Subjects
Cancer Research ,Pathology ,medicine.medical_specialty ,Mammary gland ,Cancer ,Biology ,medicine.disease ,Epithelium ,Staining ,medicine.anatomical_structure ,Breast cancer ,Cyclin D1 ,Oncology ,medicine ,Cancer research ,Carcinoma ,Immunohistochemistry - Abstract
We have used immunohistochemical staining to assess the expression of cyclin D1 in formalin-fixed sections of 345 breast carcinomas, dating back 20 years. Clinical follow-up data were available on all patients. Approximately 50% of the tumours showed excessive nuclear staining for cyclin D1 as compared with normal epithelium. Some tumours showed strong cytoplasmic staining in the absence of nuclear staining, and around 25% of the tumours were judged to be negative for nuclear cyclin D1. Contrary to expectations, moderate/strong staining for cyclin D1 was associated with improved relapse-free and overall survival relative to patients whose tumours stained weakly or negatively. Conversely, tumours that were considered negative for cyclin D1 staining had an adverse prognosis, and the poor outcome was further accentuated if the tumours were also oestrogen receptor-negative. A possible explanation for our findings is that tumours in which cyclin D1 levels are abnormally low may have sustained mutations in other genes, such as RBI and that it is this abnormality that has the more significant impact on survival from breast cancer.
- Published
- 1996
11. Cognitive responses and psychiatric disorder in women with operable breast cancer
- Author
-
Amanda Ramirez, Walter M Gregory, Karen L. Pinder, and Michael Richards
- Subjects
medicine.medical_specialty ,business.industry ,media_common.quotation_subject ,Prevalence ,Patient characteristics ,Experimental and Cognitive Psychology ,Cognition ,medicine.disease ,Psychiatry and Mental health ,Optimism ,Breast cancer ,Oncology ,Medicine ,business ,Psychiatry ,Psychosocial ,media_common - Abstract
The relationships between patient characteristics, cognitive responses and psychiatric disorder have been examined in 105 women with operable breast cancer in the 6 months around the time of diagnosis. Patients underwent interview-based psychosocial assessments at approximately 6 and 20 weeks post diagnosis. Information concerning patient characteristics was obtained at the 6 week assessment. Cognitive responses were assessed using a newly developed schedule at both the 6 and 20 week assessments. Psychiatric disorder from one month prior to diagnosis to five months post diagnosis was assessed at 20 weeks using the Present State Examination and Bedford College Rating Criteria. The point prevalence of psychiatric disorder (borderline and full case) was 48% at 6 weeks and 17% at 20 weeks post diagnosis. The period prevalence for the 6 months around the time of diagnosis was 66%, with 37% of women experiencing psychiatric disorder which was unresolved 6 weeks after diagnosis (persistent psychiatric disorder). The patient characteristics independently associated with psychiatric disorder included age < 50 (p = 0.05), lack of an intimate relationship (p = 0.05) and having previous psychological difficulties (p = 0.07). The frequencies of the cognitive responses assessed were generally similar at 6 and 20 weeks. So too was the extent to which each individual response was reported by each patient at each time point. Lack of optimism was significantly associated with psychiatric disorder at 20 weeks (p = 0.04), but not at 6 weeks post diagnosis. None of the other cognitive responses assessed were related to psychiatric disorder at either assessment.
- Published
- 1994
12. The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia
- Author
-
David A. G. Galton, Walter M Gregory, Daniel Catovsky, and Junia V. Melo
- Subjects
medicine.medical_specialty ,Univariate analysis ,Scoring system ,Lymphocytic leukaemia ,business.industry ,Chronic lymphocytic leukemia ,Prolymphocytic leukaemia ,Prolymphocyte Count ,Spleen ,Hematology ,Prognosis ,medicine.disease ,Gastroenterology ,Leukemia, Lymphoid ,Leukocyte Count ,medicine.anatomical_structure ,hemic and lymphatic diseases ,Internal medicine ,Humans ,Medicine ,business ,Prolymphocytic leukemia - Abstract
The prognostic value of biological, clinical and laboratory features was analysed in a series of 265 patients with chronic lymphocytic leukaemia (CLL) and prolymphocytic leukaemia (PLL). On univariate analysis seven features were shown to influence significantly the survival of the whole group of patients: absolute prolymphocyte count (ABS PROL), percentage of prolymphocytes (%PROL), WBC, spleen size, age, intensity of surface-membrane immunoglobulin (SmIg) and mouse (M) rosettes. Multivariate regression analysis of these features showed that only ABS PROL and spleen size had independent prognostic significance. The survival in PLL (38 cases) was significantly shorter than in CLL (227 cases) (median survival = 3 and 8 years, respectively). Patients with CLL with an increased %PROL (11-55%), defined as CLL/PL, could be divided into two groups: those with ABS PROL less than or equal to 15 X 10(9)/l (26 cases) fell within the 'standard-prognostic risk' for typical CLL (i.e. less than or equal to 10% PROL), whereas the survival outlook for the cases with ABS PROL greater than 15 X 10(9)/l (40 cases) was as bad as for PLL. A scoring system was generated with the four features that showed high prognostic significance: ABS PROL, spleen size, SmIg and M-rosettes. The score proved to be superior to any single feature as a predictor of survival, being especially useful in the analysis of the CLL/PL group: cases with high scores (greater than 2) had a median survival of 2.5 years, while the median has not been reached for those with low scores (less than or equal to 2). We suggest that this scoring system may help to identify the cases of CLL/PL that behave as PLL, and as such may benefit from different treatment.
- Published
- 1987
13. Chemotherapy and immunotherapy for acute myelogenous leukemia
- Author
-
S. A. N. Johnson, Walter M Gregory, T. A. Lister, A. M. Paxton, R. Bell, R. T. D. Oliver, Peter F. M. Wrigley, M. H. Cullen, J. M. A. Whitehouse, J. M. Ford Mrcp, and James S. Malpas
- Subjects
Cancer Research ,Chemotherapy ,Vincristine ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Complete remission ,Immunotherapy ,medicine.disease ,Surgery ,Leukemia ,Myelogenous ,Oncology ,medicine ,Prednisolone ,business ,Median survival ,medicine.drug - Abstract
Eighty-six consecutive untreated adults with acute myelogenous leukemia were treated with a combination of Adriamycin, vincristine, prednisolone, Cytosine Arabinoside, and BCG. Complete remission was achieved in 39 (45%) patients; these patients were then allocated on an alternate basis to receive BCG and monthly chemotherapy with or without weekly irradiated allogeneic blast cells. The median duration of remission was eight months and was the same for both groups. The median survival of those achieving complete remission was 19 months compared with two months for those not achieving complete remission. Nine patients are still alive without relapse and five of these patients have been disease free for more than three years.
- Published
- 1980
14. Lymphoplasmacytoid and small cell centrocytic non-Hodgkin's lymphoma—A retrospective analysis from St Bartholomew's hospital 1972–1986
- Author
-
H. S. Dhaliwal, P. A. Hall, T. A. Lister, M. A. Richards, Alfred G. Stansfeld, J. A. L. Amess, and Walter M Gregory
- Subjects
Cancer Research ,medicine.medical_specialty ,Vincristine ,Cyclophosphamide ,Gastroenterology ,hemic and lymphatic diseases ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,London ,medicine ,Humans ,Retrospective Studies ,Chlorambucil ,business.industry ,Lymphoma, Non-Hodgkin ,Incidence (epidemiology) ,Remission Induction ,Age Factors ,Hematology ,General Medicine ,Prognosis ,medicine.disease ,Combined Modality Therapy ,Lymphoma ,Non-Hodgkin's lymphoma ,Surgery ,Oncology ,Localized disease ,Prednisolone ,Prednisone ,business ,medicine.drug - Abstract
Lymphoplasmacytoid (lpc) and small cell centrocytic (scc) lymphoma are the two major sub-types of diffuse low grade non-Hodgkin's Lymphoma (NHL) within the Kiel classification. The presentation features and outcome for all 112 patients with these diagnoses (60 lpc, 52 scc) managed at St Bartholomew's Hospital between 1972 and 1986 are presented. The outcome for these patients is compared with that for patients with follicular and high grade lymphomas managed at this hospital during the same period. Nineteen of the 112 patients had localized (stages I-IIE) disease. In 18 of these cases the primary site of disease was extranodal, the gastrointestinal tract being involved in 12 cases. The survival for patients with localized disease was excellent. Eighteen are currently alive with median follow-up of 8 years. Ninety-three patients had advanced disease. A high incidence of splenomegaly, hepatomegaly, bone marrow and peripheral blood involvement was observed in both histological subgroups. A monoclonal paraprotein band was detected in the serum of nearly 50 per cent of patients with advanced lpc lymphoma. Patients with advanced disease were treated with either chlorambucil or cyclophosphamide, vincristine and prednisolone (CVP). The outcome was similar for both histological groups. Survival for these patients was poor (median 40 months) with less than 20 per cent surviving 5 years. Advanced age, elevated aspartate transaminase and failure to respond to treatment were identified by multivariate regression analysis as adverse prognostic factors.
- Published
- 1989
15. APPARENT REMOVAL OF GRAFT-VERSUS-LEUKAEMIA EFFECT BY THE USE OF LEUCOCYTE-POOR BLOOD COMPONENTS IN PATIENTS WITH ACUTE MYELOBLASTIC LEUKAEMIA
- Author
-
Michael F. Murphy, Walter M Gregory, A. Z. S. Rohatiner, A. H. Waters, J. Lim, J. Tucker, and T. A. Lister
- Subjects
Adult ,medicine.medical_specialty ,Adolescent ,business.industry ,Hematology ,Middle Aged ,Gastroenterology ,Graft versus leukaemia ,Leukemia, Myeloid, Acute ,Internal medicine ,Leukocytes ,Humans ,Medicine ,Blood Transfusion ,In patient ,business ,Acute myeloblastic leukaemia - Published
- 1989
16. MT2 immunoreactivity, cellular proliferation and prognosis in B-cell non-Hodgkin's lymphoma
- Author
-
Walter M Gregory, P. A. Hall, and A. G. Stansfeld
- Subjects
Cell kinetics ,Pathology ,medicine.medical_specialty ,Histology ,Cell division ,Pathology and Forensic Medicine ,Antigen ,Antigens, Neoplasm ,medicine ,Humans ,B cell ,biology ,business.industry ,Lymphoma, Non-Hodgkin ,Antibodies, Monoclonal ,General Medicine ,Prognosis ,medicine.disease ,Lymphoma ,Non-Hodgkin's lymphoma ,medicine.anatomical_structure ,Monoclonal ,biology.protein ,Antibody ,business ,Cell Division - Published
- 1989
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.